HCA
VKTX icon

Harbour Capital Advisors’s Viking Therapeutics VKTX Stock Holding History

Harbour Capital Advisors’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$473K Sell
12,170
-595
-5% -$19.2K 0.09% 197
2026
Q1 		$437K Sell
12,765
-245
-2% -$7.88K 0.08% 198
2025
Q4 		$461K Buy
+13,010
New +$461K 0.09% 182

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Harbour Capital Advisors's VKTX Position: Q2 2026 in Review

Harbour Capital Advisors reduced its Viking Therapeutics (VKTX) stake by 4.7% in Q2 2026, selling an estimated $19.2K and leaving 12,170 shares worth $473K. The position accounts for 0.09% of the portfolio, ranked #197.

Harbour Capital Advisors first reported a position in VKTX in Q4 2025 and has held it in 3 quarters since. 432 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • Harbour Capital Advisors held 12,170 shares of Viking Therapeutics worth $473K as of Q2 2026.
  • Harbour Capital Advisors sold 595 Viking Therapeutics shares in Q2 2026, an estimated $19.2K.
  • Viking Therapeutics made up 0.09% of Harbour Capital Advisors's portfolio in Q2 2026, its #197 holding.
  • Harbour Capital Advisors first reported a position in Viking Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 432 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Harbour Capital Advisors's 13F filing for Q2 2026, filed 15 Jul 2026.